Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance

Malaria continues to exact a great human toll in tropical settings. Antimalarial resistance is rife and the parasite inexorably develops mechanisms to outwit our best drugs, including the now first-line choice, artesunate. Novel strategies to circumvent resistance are needed. Here we detail drug dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahinas, Dea, Folefoc, Asongna, Pillai, Dylan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235713/
https://www.ncbi.nlm.nih.gov/pubmed/25436880
http://dx.doi.org/10.3390/pathogens2010033
_version_ 1782345066618028032
author Shahinas, Dea
Folefoc, Asongna
Pillai, Dylan R.
author_facet Shahinas, Dea
Folefoc, Asongna
Pillai, Dylan R.
author_sort Shahinas, Dea
collection PubMed
description Malaria continues to exact a great human toll in tropical settings. Antimalarial resistance is rife and the parasite inexorably develops mechanisms to outwit our best drugs, including the now first-line choice, artesunate. Novel strategies to circumvent resistance are needed. Here we detail drug development focusing on heat shock protein 90 and its central role as a chaperone. A growing body of evidence supports the role for Hsp90 inhibitors as adjunctive drugs able to restore susceptibility to traditionally efficacious compounds like chloroquine.
format Online
Article
Text
id pubmed-4235713
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42357132014-11-25 Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance Shahinas, Dea Folefoc, Asongna Pillai, Dylan R. Pathogens Review Malaria continues to exact a great human toll in tropical settings. Antimalarial resistance is rife and the parasite inexorably develops mechanisms to outwit our best drugs, including the now first-line choice, artesunate. Novel strategies to circumvent resistance are needed. Here we detail drug development focusing on heat shock protein 90 and its central role as a chaperone. A growing body of evidence supports the role for Hsp90 inhibitors as adjunctive drugs able to restore susceptibility to traditionally efficacious compounds like chloroquine. MDPI 2013-02-04 /pmc/articles/PMC4235713/ /pubmed/25436880 http://dx.doi.org/10.3390/pathogens2010033 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Shahinas, Dea
Folefoc, Asongna
Pillai, Dylan R.
Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
title Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
title_full Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
title_fullStr Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
title_full_unstemmed Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
title_short Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
title_sort targeting plasmodium falciparum hsp90: towards reversing antimalarial resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235713/
https://www.ncbi.nlm.nih.gov/pubmed/25436880
http://dx.doi.org/10.3390/pathogens2010033
work_keys_str_mv AT shahinasdea targetingplasmodiumfalciparumhsp90towardsreversingantimalarialresistance
AT folefocasongna targetingplasmodiumfalciparumhsp90towardsreversingantimalarialresistance
AT pillaidylanr targetingplasmodiumfalciparumhsp90towardsreversingantimalarialresistance

Ejemplares similares